Fulgent Genetics (NASDAQ: FLGT) net income
Fulgent Genetics reported a net loss of $60.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $42.7m.
Fulgent Genetics's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −71.7%. It reported a loss in 7 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | −$60.5m | — | −18.8% |
| 2024 | −$42.7m | — | −15.1% |
| 2023 | −$167.8m | −217.0% | −58.0% |
| 2022 | $143.4m | −71.7% | 23.2% |
| 2021 | $507.4m | +136.7% | 51.1% |
| 2020 | $214.3m | — | 50.8% |
| 2019 | −$0.4m | — | −1.3% |
| 2018 | −$5.6m | — | −26.3% |
| 2017 | −$2.5m | — | −13.4% |
| 2016 | −$5.3m | — | −29.3% |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Fulgent Genetics net income compared with its sector
By net income for its latest fiscal year, Fulgent Genetics ranks 277th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Fulgent Genetics, −18.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 275th | Climb Bio | −$59.9m | — |
| 276th | Contineum Therapeutics | −$60.0m | — |
| 277th | Fulgent Genetics | −$60.5m | −18.8% |
| 278th | STLN | −$60.6m | −12.1% |
| 279th | Ardelyx | −$61.6m | −15.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Fulgent Genetics
- How much did Fulgent Genetics earn in fiscal 2025?
- Fulgent Genetics reported a net loss of $60.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $42.7m.
- What was the most profitable year for Fulgent Genetics?
- Of its last 10 fiscal years, fiscal 2021, with $507.4m.
- Where does Fulgent Genetics rank in its sector by net income?
- It ranks 277th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Fulgent Genetics come from?
- From the annual report (Form 10-K) that Fulgent Genetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Fulgent Genetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Fulgent Genetics: the Fulgent Genetics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.